ESR1 Mutations Affect Anti-proliferative Responses to Tamoxifen through Enhanced Cross-Talk with IGF Signaling

It is now generally accepted that estrogen receptor (ESR1) mutations occur frequently in metastatic breast cancers, however we do not yet know how to best treat these patients. We have modeled the three most frequent hormone binding ESR1 (HBD-ESR1) mutations (Y537N, Y537S, and D538G) using stable le...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast Cancer Res Treat
Autori principali: Gelsomino, Luca, Gu, Guowei, Rechoum, Yassine, Beyer, Amanda R, Pejerrey, Sasha M, Tsimelzon, Anna, Wang, Tao, Huffman, Kenneth, Ludlow, Andrew, Ando’, Sebastiano, Fuqua, Suzanne AW
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5510243/
https://ncbi.nlm.nih.gov/pubmed/27178332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3829-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi